StreetInsider.com News Articles

Hims shares set for best week on record after new Novo Nordisk deal

Fri, 13 Mar 2026 10:09:31 -0400

Investing.com - Hims & Hers Health Inc. shares are heading toward their strongest weekly performance on record following a new partnership with Novo Nordisk A/S that has reignited investor confidence in the company's weight-loss drug business.

The San Francisco-based telehealth company's stock jumped at the open on Friday before settling to gains of about 2% as of shortly after 10AM. The advance builds on a 51% surge for the week through Thursday's close. Shares have climbed in three of the past four trading sessions, reaching a one-month high.

Earlier this week, Hims said it would partner with Novo to sell Ozempic and

Hims shares set for best week on record after new Novo Nordisk deal

Fri, 13 Mar 2026 10:09:31 -0400

Earlier this week, Hims said it would partner with Novo to sell Ozempic and

Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK300 at Berenberg

Thu, 12 Mar 2026 05:32:38 -0400

Berenberg analyst Kerry Holford lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK300.00 (from DKK360.00) while maintaining a Buy rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK300 at Berenberg

Thu, 12 Mar 2026 05:32:38 -0400

Berenberg analyst Kerry Holford lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK300.00 (from DKK360.00) while maintaining a Buy rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK300 at Berenberg

Thu, 12 Mar 2026 05:32:38 -0400

Berenberg analyst Kerry Holford lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK300.00 (from DKK360.00) while maintaining a Buy rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK300 at Berenberg

Thu, 12 Mar 2026 05:32:38 -0400

Berenberg analyst Kerry Holford lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK300.00 (from DKK360.00) while maintaining a Buy rating.

Novo Nordisk issued FDA warning letter over adverse event reporting

Tue, 10 Mar 2026 09:38:22 -0400

(Updated - March 10, 2026 9:38 AM EDT)

Novo Nordisk Inc. (NYSE: NVO) received a warning letter from the U.S. Food and Drug Administration for violations of postmarketing adverse drug experience reporting requirements, according to an FDA document dated January 2025.

The FDA conducted an inspection of Novo Nordisk's U.S. operations between January 13 and February 7, 2025, focusing on the company's compliance with adverse event reporting regulations for products containing semaglutide, liraglutide, nedosiran sodium, and estradiol.

The agency identified failures in developing written procedures for surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences. The FDA found that Novo Nordisk's procedures

Novo Nordisk issued FDA warning letter over adverse event reporting

Tue, 10 Mar 2026 09:38:22 -0400

(Updated - March 10, 2026 9:38 AM EDT)

Novo Nordisk issued FDA warning letter over adverse event reporting

Tue, 10 Mar 2026 09:38:22 -0400

(Updated - March 10, 2026 9:38 AM EDT)

BMO Capital Shares Thoughts on Novo Nordisk (NVO) Following The Hims Agreement

Tue, 10 Mar 2026 08:50:59 -0400

BMO Capital analyst Evan Seigerman reiterated a Market Perform rating and $45.00 price target on Novo Nordisk (NYSE: NVO).

The analyst commented: "Novo and Hims Bury the Hatchet With Platform Agreement; If you can't beat 'em...Novo and Hims to partner on sale of branded GLP1s; Hims will shift away from sales and marketing of most compounded product (not all). We see this as a significant step forward for Novo in dealing with a major commercial headwind. With this deal Hims will stop marketing compounded semaglutide, but will still offer customized dosing, in select cases. We suspect that pressure from the Novo

Novo Nordisk downgraded as pipeline 'not poised to blunt semaglutide LOE'

Tue, 10 Mar 2026 08:27:30 -0400

Investing.com -- TD Cowen has downgraded Novo Nordisk to Hold, warning that the drugmaker faces “enormous challenges” ahead of semaglutide’s loss of exclusivity (LOE).

Analyst Michael Nedelcovych writes that while Novo Nordisk “can be fairly credited with unlocking the obesity market’s potential,” it is “no longer clear the pipeline can answer the call.”

TD Cowen says its downgrade follows a series of setbacks across key programs. “CagriSema trials have failed or underwhelmed, and Ozempic prescriptions keep lagging,” the firm notes, adding that insights from its recent Health Care Conference “offered additional reasons for caution.”

Although the Wegovy Pill launch

Novo Nordisk downgraded as pipeline 'not poised to blunt semaglutide LOE'

Tue, 10 Mar 2026 08:27:30 -0400

Investing.com -- TD Cowen has downgraded Novo Nordisk to Hold, warning that the drugmaker faces “enormous challenges” ahead of semaglutide’s loss of exclusivity (LOE).

Analyst Michael Nedelcovych writes that while Novo Nordisk “can be fairly credited with unlocking the obesity market’s potential,” it is “no longer clear the pipeline can answer the call.”

Although the Wegovy Pill launch

TD Cowen Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold

Tue, 10 Mar 2026 03:01:22 -0400